WO2006067866A1 - Composition contenant de la proanthocyanidine - Google Patents

Composition contenant de la proanthocyanidine Download PDF

Info

Publication number
WO2006067866A1
WO2006067866A1 PCT/JP2004/019791 JP2004019791W WO2006067866A1 WO 2006067866 A1 WO2006067866 A1 WO 2006067866A1 JP 2004019791 W JP2004019791 W JP 2004019791W WO 2006067866 A1 WO2006067866 A1 WO 2006067866A1
Authority
WO
WIPO (PCT)
Prior art keywords
proanthocyanidins
weight
pine
extract
pine bark
Prior art date
Application number
PCT/JP2004/019791
Other languages
English (en)
Japanese (ja)
Inventor
Kinya Takagaki
Takeshi Mitsui
Original Assignee
Toyo Shinyaku Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyo Shinyaku Co., Ltd. filed Critical Toyo Shinyaku Co., Ltd.
Priority to PCT/JP2004/019791 priority Critical patent/WO2006067866A1/fr
Publication of WO2006067866A1 publication Critical patent/WO2006067866A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Definitions

  • the present invention relates to a composition for enhancing the bioactive action of proanthocyanidins.
  • Proanthocyanidins are condensed or polymerized tannins (hereinafter referred to as polycondensation) present in various plants, and are a group of compounds obtained by polycondensation with flavan_3_ol or flavan-3,4-diol as structural units. is there. These are given their names because they produce anthocyanidins such as cyanidin, delphiyudin and pelargonidin by acid treatment.
  • oligomeric proanthocyanidin hereinafter referred to as OPC.
  • Proanthocyanidins are a kind of polyphenols and have a strong antioxidant action (Patent No. 3 0 40 9 92 2). Furthermore, they suppress bacterial growth in the oral cavity and prevent plaque (teeth It is known that it has the effect of reducing the elasticity of the blood vessels (the effect of protecting the blood vessels) (the effect of protecting the blood vessels); the effect of increasing the utilization efficiency of vitamin C; and the effect of improving the fluidity of blood.
  • An object of the present invention is to provide a novel composition that can further enhance various physiologically active actions of proanthocyanidins.
  • the present inventors have made extensive studies on the above problems, and surprisingly, the combination of proanthocyanidins and xanthine derivatives surprisingly improves the lipid metabolism of proanthocyanidins, improves lipids in blood, and improves exercise capacity. It is possible to remarkably enhance the effects on the living body such as effects, blood flow improvement effect, diet effect, slimming effect, etc., and it was found that these effects are excellent effects that cannot be obtained by single administration. It came to complete.
  • composition of the present invention contains proanthocyanidins and xanthine derivatives.
  • the xanthine derivative is caffeine.
  • the proanthocyanidins are derived from pine bark. Brief Description of Drawings
  • Fig. 1 shows the swimming of rats when a sample solution containing a pine bark extract and caffeine, a sample solution containing only a pine bark extract, and a sample solution containing only caffeine are taken. It is a graph which shows time.
  • composition of the present invention contains a proanthocyanidin and a xanthine derivative, and contains other components as necessary. Hereinafter, each component will be described.
  • proanthocyanidins used in the present invention those containing a large amount of a condensation polymer having a low polymerization degree are suitable.
  • a condensation polymer having a low degree of polymerization a condensation polymer having a degree of polymerization of 2 to 30 (2 to 30 mer) is preferable, and a condensation polymer having a degree of polymerization of 2 to 10 (2 to 10 mer) ) Is more preferred, and a condensation polymer having a degree of polymerization of 2 to 4 (2 to 4 mer: more preferably 0 to 0.
  • Proanthocyanidins are concentrated in plant leaves, bark, fruit peels or seed parts.
  • Proanthocyanidins are specifically the bark of plants such as pine, cocoons and wild peaches; buds, blueberries, strawberries, apogados, black acacias, berries and seeds; Included in barley, wheat, soybeans, black soybeans, cacao, red beans, tochi husks, peanut skins, gypsophila leaves, etc.
  • West African cola nuts, Peruvian latania roots, Japanese green tea are also known to contain OPC.
  • OPC is a substance that cannot be produced in the human body.
  • proanthocyanidins with high OPC content or extracts containing proanthocyanidins with high OPC content compared to the case of using proanthocyanidins with a high degree of polymerization (low OPC content).
  • an excellent blood flow improvement effect and an improvement effect of exercise ability such as an improvement of muscle strength can be obtained.
  • further Improving muscular strength is effective in improving basal metabolism and may contribute to dietary effects.
  • materials such as the bark of the above-mentioned plant, pulverized fruits or seeds, or extracts thereof can be used.
  • a plant-derived extract it is preferable to use a plant-derived extract, and it is particularly preferable to use a pine bark-derived extract. Extracts derived from pine bark show a particularly high physiological activity among plant-derived extracts. This is thought to be because, among the plants containing proanthocyanidins, pine bark is rich in OPC, or contains active ingredients in addition to proanthocyanidins. Therefore, pine bark is preferably used as a raw material for proanthocyanidins.
  • the extract is preferably one from which impurities have been removed.
  • Pine bark extract includes French coastal pine (Pinus Martima), larch, black pine, akamatsu, himekomatsu, pine pine, pine pine, wild pine, eucalyx pine, pine pine, pine pine, white pine, Canadian quebec An extract of a bark of a plant belonging to the order of pine is preferably used. Among them, the bark extract of French maritime pine (Pinus Martima) is preferred.
  • French coastal pine is a marine pine that grows on the Atlantic coast of southern France.
  • This French coastal pine bark contains proanthocyanidins, organic acids, and other physiologically active ingredients, and its main component, broanthocyanidins, has a strong antioxidant action to remove active oxygen. It has been known.
  • the pine bark extract is obtained by extracting the pine bark with water or an organic solvent. When water is used, it is preferable to use warm water or hot water. In order to improve the extraction efficiency, it is preferable to add a salt such as sodium chloride to these waters.
  • Organic solvents used for extraction are used in the production of food or drugs.
  • Acceptable organic solvents are used, such as methanol, ethanol, 1-propanol, 2_propanol, 1-butanol, 2-butanol, acetone, hexane, cyclohexane, propylene glycol, hydrous ethanol, Hydrous propylene glycol, methyl ethyl ketone, glycerin, methyl acetate, ethyl acetate, jetyl ether, dichloromethane, edible oils and fats, 1, 1, 1, 2-tetrafluoroethane, and 1, 1, 2-trichloroethene Are listed.
  • These water and organic solvents may be used alone or in combination.
  • water, hot water, ethanol, water-containing ethanol, and water-containing propylene glycol are preferable, and water, hot water, ethanol, and water-containing ethanol are more preferable from the viewpoint of safety when used in foods and pharmaceuticals.
  • the method for extracting proanthocyanidins from pine bark is not particularly limited. For example, by extracting 1 to 100 parts by weight of hot water of 50 to 120 ° C, preferably 70 to 100 ° C with respect to 1 part by weight of the dry weight of pine bark. A pine bark extract having high bioactivity and high water solubility can be obtained. A warm extraction method, a supercritical fluid extraction method, or the like may be used.
  • supercritical fluid extraction may be performed by an entrainer addition method.
  • ethanol, propanol, n-hexane, acetone, toluene, other aliphatic lower alcohols, aliphatic hydrocarbons, aromatic hydrocarbons, or ketones are added to a supercritical fluid.
  • the solubility of the target extract such as OPC and catechins (described later) in the extraction solvent is dramatically increased.
  • it is a method for enhancing the selectivity of separation, and a method for efficiently obtaining a pine bark extract.
  • the pine bark extract obtained by the above extraction may be purified for the purpose of increasing the proanthocyanidin content.
  • a solvent such as ethyl acetate is usually used, but from the viewpoint of safety as a food or pharmaceutical, a method that does not use a solvent, such as ultrafiltration or Diaion HP-2O, Sephadex It is preferable to purify by a column method or a batch method using an adsorbent carrier such as LH 20 or chitin.
  • the pine bark extract containing proanthocyanidin as a main component is specifically prepared by the following method, but this is an example and is not limited to this method.
  • the washing step is repeated twice, in which the precipitate is added again to 1 L of chloroform and precipitated.
  • the precipitate is added again to 1 L of chloroform and precipitated.
  • the extract derived from the raw material plant such as pine husk preferably contains 40% by weight or more of proanthocyanidins.
  • this source plant derived The extract preferably contains 20% by weight or more of OPC, more preferably 30% by weight or more.
  • a pine bark extract is preferably used as a raw material containing proanthocyanidins in a high proportion.
  • OPC is an antioxidant, it has the effect of reducing the risk rate of adult diseases such as cancer, heart disease, and cerebral thrombosis, and has the effect of improving the allergy in nature such as arthritis, atopic dermatitis, and hay fever.
  • it suppresses bacterial growth in the oral cavity and reduces plaque (dental glands); restores the elasticity of blood vessels; prevents lipoproteins in the blood from being damaged by active oxygen; It also has the effect of preventing cholesterol from adhering to the inner wall of blood vessels and adhering cholesterol; the effect of regenerating vitamin E decomposed by active oxygen; and the effect of enhancing vitamin E.
  • the plant extract such as the pine bark extract preferably contains catechins together with proanthocyanidins, particularly OPC.
  • Catechin is a general term for polyhydroxyflavan 1-3-ol.
  • the catechins are (+)-force techin (referred to as catechin in the narrow sense), (1) one epi force tekin, (+)-gallocatechin, (1) one epicarocatechin, epicarocatechin gallate, epicatechin gallate, Afzerekin is known. From the above-mentioned extracts derived from raw materials such as pine bark, in addition to the above (+)-power techin, gallocatechin, afuzerekin, (+)-catechin 3-galloyl derivative, and 3-galloyl derivative of gallocatechin It has been isolated.
  • Catechins are poorly water-soluble by themselves and have low physiological activity. However, catechins have the property of being activated at the same time as water solubility increases in the presence of OPC, and they act effectively when ingested with
  • Catechins are preferably contained in the raw material plant extract in an amount of 5% by weight or more, preferably 10% by weight or more. More preferably, the extract contains 20% by weight or more and 20% by weight or more of catechins.
  • the catechin content of the extract is less than 5% by weight, force techins may be added to adjust the final content to 5% by weight or more. It is most preferable to use a pine husk extract containing 20% by weight or more of the same and 5% by weight or more of the strength techins.
  • Typical xanthine derivatives used in the present invention include caffeine, theofylline, theobromine and the like. Caffeine is preferable. These are contained in palatable food materials such as tea, coffee beans, cacao, kola, guarana, mate tea and cola. As the xanthine derivative, a commercially available synthetic product or purified product may be used. However, when the composition of the present invention is orally administered (taken), the above-mentioned palatability food material or its extraction is used from the viewpoint of safety. It is preferable to use a product. These materials can contain a relatively large amount of caffeine.
  • a xanthine derivative is a material that efficiently enhances a plurality of bioactive actions of proanthocyanidins.
  • Xanthine derivatives alone, are known to cause central nervous system excitement, and are contained in pharmaceuticals and foods for the purpose of awakening sleepiness and relieving fatigue.
  • it has smooth muscle relaxation and anti-inflammatory effects, and is used as a medicine for colds and asthma.
  • it has a diuretic effect, an increase in heart rate, and a slight basal metabolism improving effect due to fatty acid degradation, and a diet effect. (Other ingredients)
  • the composition of the present invention contains the above proanthocyanidins and xanthine derivatives. If necessary, it can contain various components. For example, ingredients that can be added as normal foods and pharmaceuticals (excipients, bulking agents, binders, thickeners, emulsifiers, colorants, fragrances, nutritional ingredients, food additives, etc.); and cosmetics, quasi drugs Ingredients commonly used as external preparations for skin (whitening agents, moisturizers, antioxidants, UV absorbers, UV scattering agents, antiseptics, fragrances, gelling agents, polymer polymers, oily ingredients, surfactants, Thickeners, alcohols, powder ingredients, colorants, aqueous ingredients, various skin nutrients, etc.).
  • ingredients that can be added as normal foods and pharmaceuticals excipients, bulking agents, binders, thickeners, emulsifiers, colorants, fragrances, nutritional ingredients, food additives, etc.
  • cosmetics quasi drugs
  • Ingredients commonly used as external preparations for skin whitening agents, moisturizers,
  • Nutritional ingredients include, for example, vitamins such as ascorbic acid, tocopherol, riboflavin, / 3-carotene, folic acid and piotin; minerals such as calcium, magnesium, selenium, iron; and taurine and garlic.
  • Flavanoids such as hesperidin and quercetin; Flavonoids; Dietary fibers such as indigestible dextrin, alginic acid, chitin, chitosan and guagam; Proteins such as soy protein and collagen; Peptide; Amino acid; Animal fats and oils such as milk fat, lard, beef tallow and fish oil; vegetable oils such as soybean oil and rapeseed oil; fruits such as orange, lemon, grapefruit and strawberry and their juices; royal jelly, propolis and the like. Examples of food-added calories include honey, reduced maltose, lactose, sugar alcohol, liquid sugar, and seasonings. (Proanthocyanidin-containing composition)
  • the composition of the present invention contains a proanthocyanidin and a xanthine derivative, and, if necessary, contains other components.
  • the proanthocyanidins and xanthine derivatives may be any of isolated compounds, food materials containing them, and extracts of the food materials.
  • a plant extract containing a xanthine derivative is added to a plant extract containing proanthocyanidins.
  • blowers such as pine bark and grape seeds
  • a plant extract containing a xanthine derivative is added to a plant extract containing toxanidine and not containing a xanthine derivative or purified to contain a high concentration of proanthocyanidins.
  • the necessary ingredients for example, pine bark extract containing proanthocyanidins
  • the amount ratio of each component can be adjusted as appropriate.
  • the content ratio of proanthocyanidins and xanthine derivatives in the composition of the present invention is arbitrary.
  • the ratio of proanthocyanidins to xanthine derivatives is from 1: 0.001 to 1000 by weight, more preferably from 1: 0.01 to 1: 500, more preferably from 1: 0.02 to 1: 200, most preferably 1: 0.0.02 :: 1: 50.
  • proanthocyanidin in the composition of this invention is preferably contained so that the daily intake per adult is 1 to 1000 mg, more preferably 2 to 500 mg as proanthocyanidins.
  • transdermal administration since it is a topical administration, it is preferable to have a predetermined concentration.
  • proanthocyanidins are preferably contained in the composition in an amount of 0.0001% to 20% by weight. / 0 , more preferably 0.0001 wt% to 10 wt%, and even more preferably 0.001 wt% to 10 wt%.
  • a xanthine derivative is a composition. Among them, preferably 0.0 0 0 0 1% by weight to 20% by weight, more preferably 0.0 0 0 1%. /.
  • composition of the present invention can be prepared in various forms depending on the purpose, for example, as a food, a pharmaceutical, a quasi-drug, or a cosmetic.
  • composition of the present invention when the composition of the present invention is orally ingested (administered) as food, pharmaceuticals, quasi drugs, etc., there is no particular limitation on the form.
  • capsules such as hard capsules and soft capsules, tablets, pills, powder (powder), granules, tea bags, bowl-like viscous liquids, liquids, pastes, etc. are used in a form commonly used by those skilled in the art. .
  • These can be taken as they are, or they can be taken in water, hot water, milk, etc., depending on the shape or taste, or you can take the brewed ingredients.
  • composition of the present invention is applied to the skin as a quasi-drug, cosmetic, etc.
  • these forms are not particularly limited, such as ointments, creams, emulsions, lotions, packs, poultices, bath preparations, etc. Any form can be used as long as it is conventionally used for an external preparation for skin.
  • composition of the present invention can be administered orally (taken) or transdermally (applied) to improve the lipid metabolism of proanthocyanidins, improve blood lipids, improve exercise capacity, improve blood flow.
  • Physiological activity such as diet effect and slimming effect can be remarkably enhanced. These effects are excellent effects that cannot be obtained when proanthocyanidins and xanthine derivatives are administered alone.
  • the composition of the present invention can be used for foods, pharmaceuticals, quasi drugs, cosmetics and the like.
  • a pine bark extract (trade name: Frapangenol, Toyo Shinyaku Co., Ltd.) containing 40% by weight of proanthocyanidins as a material containing proanthocyanidins (containing 20% by weight of OPC as material).
  • Caffeine derived from coffee (caffeine content: 98.5% by weight) (trade name: Chanomoto, Shiratori Pharmaceutical Co., Ltd.) was used as the xanthine derivative.
  • a purified diet was prepared: corn starch 29.49 by weight 0/0, milk casein 20 wt 0/0, Alf alpha meal 1 0 wt 0/0, alpha-potato starch 10 weight 0/0 , cellulose powder 10 weight 0/0, Shiyukuro scan 10 weight 0/0, soybean oil 6% by weight, mineral mixture (AIN- 76) 3. 5 by weight 0/0, vitamin mixture (AIN-76) 1 wt 0 / 0 , and ascorbic acid 0.01% by weight. These were mixed with the refined feed so that the pine bark extract was 0.5% by weight of the whole and the power fuin was 0.01% by weight of the whole, and the solid feed was prepared by molding (prepared as feed 1). )
  • a solid feed was prepared in the same manner as in Example 1 except that caffeine was not mixed (referred to as feed 2).
  • feeds were prepared in the same manner as in Example 1 except that the pine bark extract was not mixed (referred to as feed 3).
  • Example 2 Evaluation of blood lipid metabolism improvement effect
  • Three-week-old male guinea pigs (Japan SLC Co., Ltd.) were given a commercial solid feed (RC4, Oriental Yeast Co., Ltd.) for one week to acclimatize.
  • the guinea pigs were divided into groups of 7 by a total randomization method. Each group of guinea pigs was allowed free intake of the above feeds 1-3 for 28 days.
  • a target group a group that freely consumed purified feed was established. After the intake period, the total cholesterol level, LD L cholesterol level, HDL cholesterol level, triglyceride level, and phospholipid level in each group of guinea pigs were measured. The results are shown in Table 1.
  • the measurement method is as follows.
  • Total cholesterol (m g / d L) is, using the "Serotec" TCHO- L (manufactured by stock company Serotec), it was measured by the enzymatic method.
  • LDL cholesterol (mg / d L) was measured by enzyme method using Collestest LDL (Daiichi Chemical Co., Ltd.).
  • HDL cholesterol ( mg / d L) was measured by enzyme method using Cholestest HDL (Daiichi Chemical Co., Ltd.).
  • Triglyceride (mgZdL) was measured by an enzymatic method using “Cellotech” TG-L (Seguchi Tech Co., Ltd.).
  • Phospholipid (mgZdL) was measured by an enzymatic method using “Serotech” PL-L (manufactured by Serotech Co., Ltd.). table 1
  • Sample solution 1 was prepared by dissolving in water such that the pine bark extract was 0.05% by weight and caffeine was 0.05% by weight.
  • Sample solution 2 was prepared by dissolving pine bark extract in water to 0.1% by weight.
  • Sample solution 3 was prepared by dissolving in water such that caffeine was 0.1% by weight.
  • Three 3-week-old SD male rats (Kudo Co., Ltd.) were divided into 7 groups, and each group was fed with a basic diet (MF feed: Oriental Yeast Co., Ltd.) and acclimatized for 7 days.
  • MF feed Oriental Yeast Co., Ltd.
  • One group of rats was orally administered by gavage using a sonde at a rate of lm L per day.
  • Each group of rats was orally administered. This administration was performed for 28 days. During the administration period, basic feed and water were ad libitum.
  • the group to which the sample solution containing the pine bark extract of the example and the force fuin (sample solution 1) was administered showed either one of the pine bark extract or caffeine of the comparative example. It can be seen that the swimming time is longer than that of the group ingesting the sample solutions (sample solutions 2 and 3). This indicates that the composition containing proanthocyanidins and xanthine derivatives has an excellent effect of improving athletic ability that cannot be obtained when each is taken alone.
  • Pine bark extract, caffeine, and excipients were mixed in the proportions (% by weight) shown in Table 2 to produce tablets (about 2500 mg per tablet). .
  • Example 7 the weight and body fat percentage of each subject were measured using a health meter with a body fat meter (Koyo Sangyo Co., Ltd.). After the measurement, the food 1 obtained in Example 7 was ingested at a rate of 1 tablet per day for 28 days. On the 28th day after the start of intake, body weight and body fat percentage were measured again, and the decrease rate of body weight and body fat percentage was calculated from the following formula. The same was done for foods 2 and 3, and the rate of decrease in body weight and body fat percentage was calculated. In addition, during the study, we told them that no dietary restrictions were required other than strictly observing food intake. The results are shown in Table 4. ⁇ (Food intake
  • Weight loss rate (%) (mal weight)-(weight after food intake) ⁇
  • a lotion 1 was prepared by mixing pine bark extract, caffeine, alcohol, glycerin, and 1,3-butylene glycol in the proportions shown in Table 5.
  • the balance is purified water
  • the group to which the skin lotion containing the pine bark extract of the example and caffeine (skin lotion 1) was applied contained either the pine bark extract of the comparative example or caffeine. It can be seen that the blood flow increased and the outer circumference of the upper arm decreased as compared to the group applied with lotion (lotion 2 and 3). This indicates that by applying a composition containing proanthocyanidins and a xanthine derivative, excellent blood flow improving effects and slimming effects that cannot be obtained when each of them is applied alone are obtained.
  • the composition containing proanthocyanidins and xanthine derivatives can be administered orally or transdermally to improve lipid metabolism, blood lipids, and exercise capacity of proanthocyanidins.
  • Physiological activity such as improvement effect, blood flow improvement effect, diet effect, slimming effect (local slimming effect by application) can be remarkably enhanced.
  • These effects are superior to proanthocyanidins and xanthine derivatives, which cannot be obtained by single administration. It is an effect.
  • the composition of the present invention can be effectively used for foods, pharmaceuticals, quasi drugs, cosmetics, and the like.

Abstract

L’invention a trait à une composition comprenant une proanthocyanidine et un dérivé de xanthine. Ladite composition renforce de manière remarquable les diverses activités physiologiques de la proanthocyanidine.
PCT/JP2004/019791 2004-12-24 2004-12-24 Composition contenant de la proanthocyanidine WO2006067866A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2004/019791 WO2006067866A1 (fr) 2004-12-24 2004-12-24 Composition contenant de la proanthocyanidine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2004/019791 WO2006067866A1 (fr) 2004-12-24 2004-12-24 Composition contenant de la proanthocyanidine

Publications (1)

Publication Number Publication Date
WO2006067866A1 true WO2006067866A1 (fr) 2006-06-29

Family

ID=36601479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/019791 WO2006067866A1 (fr) 2004-12-24 2004-12-24 Composition contenant de la proanthocyanidine

Country Status (1)

Country Link
WO (1) WO2006067866A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011148657A1 (fr) * 2010-05-24 2011-12-01 ハウスウェルネスフーズ株式会社 Composition pour la prévention, l'amélioration ou le traitement d'un syndrome métabolique
US11806352B2 (en) 2010-05-19 2023-11-07 Upfield Europe B.V. Theobromine for increasing HDL-cholesterol

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH104919A (ja) * 1996-06-21 1998-01-13 Toyo Seito Kk 飲食物およびその製造方法
JPH11318402A (ja) * 1998-05-11 1999-11-24 Kikkoman Corp 抗疲労ドリンク剤
JP2002119210A (ja) * 2000-10-13 2002-04-23 Riken Vitamin Co Ltd コーヒー飲料の製造法
WO2003090673A2 (fr) * 2002-04-22 2003-11-06 Rtc Research & Development, Llc. Compositions et methodes pour favoriser la perte de poids, la thermogenese, la diminution de la faim, une masse musculaire maigre, augmenter le metabolisme et amplifier les niveaux energetiques et utilisation en tant que complement alimentaire chez des mammiferes
JP2004242663A (ja) * 2002-12-20 2004-09-02 Toyo Shinyaku:Kk ダイエット食品

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH104919A (ja) * 1996-06-21 1998-01-13 Toyo Seito Kk 飲食物およびその製造方法
JPH11318402A (ja) * 1998-05-11 1999-11-24 Kikkoman Corp 抗疲労ドリンク剤
JP2002119210A (ja) * 2000-10-13 2002-04-23 Riken Vitamin Co Ltd コーヒー飲料の製造法
WO2003090673A2 (fr) * 2002-04-22 2003-11-06 Rtc Research & Development, Llc. Compositions et methodes pour favoriser la perte de poids, la thermogenese, la diminution de la faim, une masse musculaire maigre, augmenter le metabolisme et amplifier les niveaux energetiques et utilisation en tant que complement alimentaire chez des mammiferes
JP2004242663A (ja) * 2002-12-20 2004-09-02 Toyo Shinyaku:Kk ダイエット食品

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11806352B2 (en) 2010-05-19 2023-11-07 Upfield Europe B.V. Theobromine for increasing HDL-cholesterol
WO2011148657A1 (fr) * 2010-05-24 2011-12-01 ハウスウェルネスフーズ株式会社 Composition pour la prévention, l'amélioration ou le traitement d'un syndrome métabolique
KR101490730B1 (ko) * 2010-05-24 2015-02-06 하우스 웰니스 푸드 코퍼레이션 대사 증후군의 예방, 개선 또는 치료용 조성물
US9993493B2 (en) 2010-05-24 2018-06-12 House Wellness Foods Corporation Composition for prevention, amelioration or treatment of metabolic syndrome

Similar Documents

Publication Publication Date Title
CN108697685A (zh) 含有桑辛素、桑黄铜g或桑白皮的，肌肉疾病的预防及治疗用或肌功能改善用组合物
JP2003325135A (ja) 健康食品
JP2004123707A (ja) 血流改善組成物
JP2005029486A (ja) 皮膚改善組成物
JP2003146898A (ja) 高脂血症改善剤
JP4420358B1 (ja) ヒアルロン酸産生促進剤
JP2010159283A (ja) プロアントシアニジン含有組成物
EP2052729B1 (fr) Composition contre l'obésité contenant un composant issu de l'écorce d'un arbre appartenant au genre acacia
JP2005097273A (ja) 運動能力向上組成物
JP4420357B1 (ja) ヒアルロン酸産生促進剤
JP2005047839A (ja) プロアントシアニジン含有組成物
JP2003334022A (ja) 持久力向上用食品組成物
JP2005060338A (ja) プロアントシアニジン含有組成物
JP2004049135A (ja) 健康食品
JP2011195534A (ja) ヒアルロン酸産生促進剤、抗老化剤およびしわ改善剤
JP2004290102A (ja) 食品組成物
KR102172316B1 (ko) 장미꽃잎 추출물 포함 체지방 분해 및 감소용 조성물 및 이를 포함하는 건강기능식품
JP2005278654A (ja) 関節炎改善用食品
JP4400712B2 (ja) 抗酸化能増強食品
JP4648309B2 (ja) プロアントシアニジン水可溶性結合体およびそれを含有する組成物
WO2006067866A1 (fr) Composition contenant de la proanthocyanidine
WO2006057073A1 (fr) Composition augmentant la capacite athletique
AU2006347124B2 (en) Composition for preventing and/or treating itching containing component originating in the bark of tree belonging to the genus Acacia
JP2015221760A (ja) コラーゲン合成促進剤、ヒアルロン酸合成促進剤及びセラミド合成促進剤
JP2006022082A (ja) 脂質代謝改善剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 04808141

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP